Castration|resistant prostate cancer monitoring by cell|free ...

Castration-resistant prostate cancer monitoring by cell-free ...

Blood-based markers for castration-resistant prostate cancer monitoring, risk group stratification and prediction of therapy response.

Cell-free DNA in the management of prostate cancer: Current status ...

With the escalating prevalence of prostate cancer (PCa) in China, there is an urgent demand for novel diagnostic and therapeutic approaches.

An update on our ability to monitor castration-resistant prostate ...

Expert opinion: The assessment of circulating tumor DNA fraction is a valid and robust biomarker in mCRPC able to predict clinical outcome and monitor disease ...

Circulating Tumor DNA Assessment for Treatment Monitoring Adds ...

Enzalutamide after abiraterone progression is commonly used in metastatic castration-resistant prostate cancer despite a low rate of clinical benefit.

PSCA-CAR T cell therapy in metastatic castration-resistant prostate ...

Despite recent therapeutic advances, metastatic castration-resistant prostate cancer (mCRPC) remains lethal. Chimeric antigen receptor (CAR) ...

Noninvasive Detection of Neuroendocrine Prostate Cancer through ...

A cell-free DNA methylation panel was developed that can quantify tumor fraction and identify neuroendocrine prostate cancer noninvasively, which may.

Navigating therapeutic sequencing in the metastatic castration ...

Novel therapies for metastatic castration-resistant prostate cancer (mCRPC) have improved patient outcomes. However, there is uncertainty on ...

Enzalutamide Resistance in Castration-Resistant Prostate Cancer

Although tissue biopsies are impractical to perform routinely in the majority of patients with mCRPC, the analysis of plasma cell-free DNA ( ...

A Report From the First Global Prostate Cancer Consensus ...

Unfortunately, PCa cells eventually become resistant to ADT because of different resistance mechanisms thereby becoming castration-resistant PCa. This form of ...

Treatments for castration-resistant prostate cancer

Castration-resistant prostate cancer (CRPC) is cancer that continues to grow even when the testosterone levels are at or below the castrate level.

Mechanisms of resistance in castration-resistant prostate cancer ...

With the loss of the LBD on the AR as seen in ARV-7, CRPC cell lines overcome the loss of circulating and intratumoral androgens mediated by abiraterone. Loss ...

Predictors of Overall and Disease-Free Survival in Metastatic ...

Results: Seventy-three men (mean age, 69 y; range, 45–85 y) with metastatic castration-resistant prostate carcinoma were treated with 210 cycles ...

Castration-Resistant Prostate Cancer: From Uncovered ... - MDPI

Despite recent advances in diagnosis and treatment, castration-resistant prostate cancer ... The Glucocorticoid Receptor Is a Key Player for Prostate Cancer Cell ...

A Report From the First Global Prostate Cancer Consensus ...

Castration-resistant prostate cancer (CRPC) is defined by disease progression despite castrate levels of testosterone, and may present as either ...

Managing Nonmetastatic Castration-resistant Prostate Cancer

Patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) have rising prostate-specific antigen (PSA) and castrate testosterone levels.

The past, present, and future of non-metastatic castration-resistant ...

Around 10–20% of PCas acquire resistance to ADT and become castration-resistant prostate cancer (CRPC) within 5 years of follow-up. The median survival of ...

Monitoring Patients With mCRPC - Targeted Oncology

PSA 15.5 ng/mL · Family history of prostate cancer · Hypertension · Digital rectal exam and transrectal ultrasound (TRUS) of the prostate confirm ...

Understanding Androgen Dynamics in Therapy Resistance and ...

This review discusses impact of advancements in biologic understanding of prostate cancer (PCa) on definition and diagnosis of castration-resistant PCa (CRPC).

Overview of the treatment of castration-resistant prostate cancer ...

Outline · Germline genetic testing and next-generation sequencing of tumor tissue · Choice of treatment for conventional adenocarcinomas · - ...

Enzalutamide and Survival in Nonmetastatic, Castration-Resistant ...

Because metastatic, castration-resistant prostate cancer is associated with decreased overall survival, worsening quality of life, and increased ...